Grifols, S.A. (GIFLF)
| Previous close | 11.76 |
| Open | 11.76 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 11.76 - 11.76 |
| 52-week range | 7.90 - 21.00 |
| Volume | |
| Avg. volume | 659 |
| Market cap | 7.132B |
| Beta (5Y monthly) | 0.48 |
| PE ratio (TTM) | 10.84 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | 03 June 2021 |
| 1y target est | N/A |
- PR Newswire
Selagine Enters into a Collaborative Agreement with Grifols for Development and Commercialization of Immunoglobulin Eye Drops for Treating Dry Eye Disease
Selagine, Inc., a spin-out company from the University of Illinois at Chicago (UIC), announced today that it has entered into a research, development and sublicense agreement with Grifols (Nasdaq: GRFS), a global leader in plasma-derived medicines, for the development and commercialization of immunoglobulin eye drops for dry eye disease.
- PR Newswire
Grifols receives FDA clearance for AlphaID™ At Home, the first free service for U.S. consumers to determine their risk for alpha-1
Grifols (MCE: GRF) (MCE:GRF.P) (NASDAQ:GRFS), a global leader in plasma-derived medicines and innovative diagnostic solutions, today announced that its AlphaID™ At Home Genetic Health Risk Service, the first-ever free direct-to-consumer program in the U.S. to screen for genetic risk of alpha1-antitrypsin deficiency (alpha-1), has been cleared by the U.S. Food and Drug Administration (FDA).
- PR Newswire
Victor Grifols Roura decides to retire as Chairperson; Grifols appoints private equity veteran Steven F. Mayer as Executive Chairperson
Grifols (MCE: GRF) (MCE: GRF.P) (NASDAQ: GRFS) announced today changes to its leadership team, appointing Mr. Steven F. Mayer as Executive Chairperson while Mr. Victor Grifols Roura retired as Chairperson and was named Chairperson of Honor. Both changes are effective immediately.
